BIA Separations, now operating as Sartorius BIA Separations, is a leading developer and manufacturer of monolith chromatography columns for the purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA. Acquired by Sartorius in 2020, the company's proprietary CIM (Convective Interaction Media®) monolith technology offers significant advantages in bioprocessing, including high flow rates, low shear stress, and excellent resolution, particularly for gene therapies, vaccines, and other advanced biologics. They provide solutions from lab-scale research to industrial-scale manufacturing, enabling faster and more efficient biopharmaceutical production.
Global center of excellence for monolith chromatography, encompassing research, development, manufacturing, quality control, and technical support for CIM® monolith products.
State-of-the-art cGMP-compliant manufacturing facilities, advanced research and development laboratories, and dedicated application support labs. The site has seen significant investment and expansion since the Sartorius acquisition to meet growing global demand.
A highly scientific, innovative, and quality-driven environment. The culture fosters collaboration between research, production, and commercial teams, with a strong emphasis on problem-solving and customer-centric solutions within the biopharmaceutical sector. Integration with Sartorius has broadened opportunities and resources.
The Ajdovščina site is pivotal for Sartorius's advanced therapies portfolio, being the core for monolith technology development and production, crucial for manufacturing next-generation medicines.
As part of Sartorius, BIA Separations' monolith chromatography solutions are supported globally through Sartorius's extensive international network. This ensures comprehensive sales coverage, field application support, technical service, and distribution in all major biopharmaceutical markets, including the Americas, Europe, Middle East, Africa, and Asia-Pacific. Key functions supported globally include product sales, customer training, application development, and post-sales support.
Mirce 21
Ajdovščina
Goriška Region
Slovenia
Address: Various Sartorius sales and support offices worldwide.
To provide comprehensive sales, technical support, application development, and customer service for BIA Separations' monolith chromatography solutions to a global customer base, leveraging Sartorius's established infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BIA Separations' leadership includes:
BIA Separations has been backed by several prominent investors over the years, including:
Following the acquisition by Sartorius in 2020, executive leadership for BIA Separations is integrated into the Sartorius corporate structure, specifically within its Bioprocess Solutions division. Major BIA Separations-specific 'hires' or 'exits' are typically part of broader Sartorius leadership appointments or reorganizations. No major, publicly announced BIA Separations-specific executive changes have been noted in the last 12 months distinct from overall Sartorius movements.
Discover the tools BIA Separations uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
As BIA Separations is part of Sartorius, employees typically use Sartorius email addresses. The most common format for Sartorius is firstname.lastname@sartorius.com.
firstname.lastname@sartorius.com
Format
jane.doe@sartorius.com
Example
90%
Success rate
Sartorius AG • May 10, 2023
Sartorius is investing around 100 million euros to significantly expand its capacities for the manufacturing of innovative chromatography products at its site in Ajdovščina, Slovenia, the home of BIA Separations. This expansion aims to meet the high demand from the biopharmaceutical industry, particularly for products used in gene therapies....more
Sartorius AG • October 2, 2020
Sartorius acquired BIA Separations for 360 million euros, enhancing its position in downstream processing, particularly for advanced therapies. BIA Separations' monolith technology is recognized for its effectiveness in purifying large biomolecules like viruses and plasmids....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BIA Separations, are just a search away.